Brain Cancer Market Report 2026

Brain Cancer Market Overview

• Brain Cancer market size has reached to $3.35 billion in 2025 • Expected to grow to $4.76 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Rising Prevalence Of Neurological Tumors Fueling The Growth Of The Market Due To Increasing Diagnostic And Treatment Needs • Market Trend: Precision Diagnostics And Imaging Tools Improve Clinical Decision Making • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Brain Cancer Market?

Brain cancer is a disease characterized by the uncontrolled growth of abnormal cells within the brain tissue. These tumors can be malignant, spreading rapidly and interfering with normal brain function, or benign, growing slowly without spreading. It can cause a range of neurological symptoms depending on the tumor’s size and location, often requiring medical intervention such as surgery, radiation, or chemotherapy. The main product types of brain cancer management include therapeutic treatments, diagnostic imaging, surgical devices, and supportive care products. Therapeutic treatments refer to medical interventions designed to target and treat brain tumors, including chemotherapy, targeted therapy, and immunotherapy, aimed at controlling tumor growth and improving patient outcomes. The surgical procedures such as tumor resection, minimally invasive surgery, and stereotactic surgery. The diagnostic approaches including imaging techniques, biopsy, molecular testing, and genetic testing. There are supportive care services such as rehabilitation, palliative care, counseling, and follow-up care and the key end users including hospitals, specialty clinics, and research institutes.

What Is The Brain Cancer Market Growth Forecast?

The brain cancer market size is expected to see strong growth in the next few years. It will grow to $4.76 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growing demand for targeted therapies, rising adoption of immunotherapies, expanding use of minimally invasive neurosurgeries, increasing focus on early diagnosis, growing investment in oncology infrastructure. Major trends in the forecast period include advancement in AI-based diagnostic tools, development of personalized medicine solutions, innovation in immunotherapy combinations, progress in liquid biopsy technologies, and research and development in high-precision imaging systems.

What Is The Driver Of The Brain Cancer Market?

The increasing prevalence of neurological tumors is expected to propel the growth of the brain cancer market going forward. Neurological tumors refer to abnormal and often malignant growths within the brain or central nervous system that impair neurological function and require complex clinical management. The prevalence of neurological tumors is rising due to demographic shifts, such as population aging and growth, as older age increases the risk of developing brain cancers. The brain cancer supports neurological tumor prevalence by expanding diagnostic, treatment, and care services that respond to the growing patient population’s clinical needs. For instance, in January 2025, according to the American Cancer Society, a US-based non-profit organization, an estimated 14,040 new cases of brain tumors and other nervous system cancers are expected in males and 10,780 in females in 2025, with total estimated deaths of 18,330. Therefore, the increasing prevalence of neurological tumors is driving the growth of the brain cancer industry.

Key Players In The Global Brain Cancer Market

Major companies operating in the brain cancer market are Providence Health & Services, Ascension Health, Trinity Health, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Cleveland Clinic, The Mount Sinai Hospital, The University of Texas MD Anderson Cancer Center, CommonSpirit Health, City of Hope National Medical Center, Stanford Health Care, Apollo Hospitals Enterprise Limited, Elekta AB, H. Lee Moffitt Cancer Center & Research Institute Inc., Roswell Park Comprehensive Cancer Center, Fred Hutchinson Cancer Center, Fortis Healthcare Limited, Dana-Farber Cancer Institute Inc., The Johns Hopkins Hospital, The Regents of the University of California

Global Brain Cancer Market Trends and Insights

Major companies operating in the brain cancer market are focusing on developing advanced diagnostic and imaging tools, such as AI‑driven MRI segmentation platforms, to improve clinical decision-making and treatment planning. AI‑driven MRI segmentation platforms refer to software systems that use artificial intelligence to automatically identify and delineate anatomical structures or lesions on MRI scans to support faster and more consistent diagnosis and treatment planning. For instance, in July 2025, Cortechs.ai, a US‑based medical imaging software company, launched NeuroQuant Brain Tumor with enhanced AI-driven MRI segmentation models, which offer automated volumetric quantification and metastasis/meningioma segmentation that improves radiologist efficiency and diagnostic consistency compared with manual interpretation, with cloud‑based deployment and PACS integration for rapid scalability. By providing objective segmentations and volumetric reports, this innovative technology improves the efficiency and standardisation of radiologists, neurosurgeons, and neuro-oncologists while saving time and enhancing clinical consistency and diagnostic confidence. Clinicians can directly promote improved patient outcomes by monitoring tumour changes over time and gaining important insights into therapy response and disease progression.

What Are Latest Mergers And Acquisitions In The Brain Cancer Market?

In October 2024, Merck & Co. Inc., a US-based healthcare company, acquired Modifi Biosciences Inc. for approximately $1.3 billion. With this acquisition, Merck expanded its oncology pipeline by integrating Modifi’s novel cancer therapeutics targeting glioblastoma and other difficult-to-treat tumors, advancing preclinical compounds toward clinical development. Modifi Biosciences Inc. is a US-based biotechnology company developing DNA repair-targeted cancer therapies, including candidates for gliomas and other brain tumors.

What Defines the Brain Cancer Market?

The brain cancer market includes revenue earned by entities through diagnosis, surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, rehabilitation, palliative care, counseling, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Brain Cancer Market Report 2026?

The brain cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the brain cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.